Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a new study published in JACC, the flagship journal of the American College of Cardiology.
COVID-19 severity linked to autoantibodies against blood clotting protein
Study investigates the occurrence of ADAMTS13 antibodies in COVID-19 patients and their association with disease severity and lower ADAMTS13 activity. The findings suggest the need
July 3, 2023